



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

GSK269962A

Cat. No.:	HY-15556
CAS No.:	850664-21-0
Molecular Formula:	C ₂₉ H ₃₀ N ₈ O ₅
Molecular Weight:	570.6
Target:	ROCK
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 30 mg/mL (52.58 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.7525 mL	8.7627 mL	17.5254 mL
	5 mM		0.3505 mL	1.7525 mL	3.5051 mL
	10 mM		0.1753 mL	0.8763 mL	1.7525 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.08 mg/mL (3.65 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.08 mg/mL (3.65 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

GSK269962A (GSK 269962) is a potent ROCK inhibitor with IC₅₀s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A has anti-inflammatory and vasodilatory activities^[1].

IC₅₀ & Target

ROCK1 1.6 nM (IC ₅₀)	ROCK2 4 nM (IC ₅₀)	RSK1 132 nM (IC ₅₀)	MSK1 49 nM (IC ₅₀)
AKT1 955 nM (IC ₅₀)	AKT2 1350 nM (IC ₅₀)	AKT3 1510 nM (IC ₅₀)	CDK2 3500 nM (IC ₅₀)

	GSK3 α 1260 nM (IC ₅₀)								
In Vitro	GSK269962A has an IC₅₀ of 1.6 nM toward recombinant human ROCK1. GSK269962A exhibits more than 30-fold selectivity against a panel of serine/threonine kinases^[1]. GSK269962A induces vasorelaxation in precontracted rat aorta with an IC₅₀ of 35 nM^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	GSK269962A is a potent antihypertensive agent. GSK269962A (0.3, 1, and 3 mg/kg; oral gavage) induces a dose-dependent reduction in blood pressure in spontaneously hypertensive rat (SHR). The reduction of blood pressure is acute and substantial^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. <table> <tr> <td>Animal Model:</td><td>Male Sprague-Dawley rats (350-400g)^[1]</td></tr> <tr> <td>Dosage:</td><td>0.3, 1, and 3 mg/kg</td></tr> <tr> <td>Administration:</td><td>Oral gavage; 12 hours</td></tr> <tr> <td>Result:</td><td>Induced a dose-dependent reduction in blood pressure.</td></tr> </table>	Animal Model:	Male Sprague-Dawley rats (350-400g) ^[1]	Dosage:	0.3, 1, and 3 mg/kg	Administration:	Oral gavage; 12 hours	Result:	Induced a dose-dependent reduction in blood pressure.
Animal Model:	Male Sprague-Dawley rats (350-400g) ^[1]								
Dosage:	0.3, 1, and 3 mg/kg								
Administration:	Oral gavage; 12 hours								
Result:	Induced a dose-dependent reduction in blood pressure.								

CUSTOMER VALIDATION

- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Virology. 2023 Jun 21.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Doe C, et al. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA